SalioGen Therapeutics Stock
HealthTechLooking to sell SalioGen Therapeutics stock or options?
SalioGen Therapeutics has developed a genome engineering platform designed to deliver long-lasting, safe, and cost-effective non-viral gene therapies for individuals with genetic disorders. This mammal-based platform holds potential for curative non-viral gene therapy, allowing the healthcare sector to enhance processes in cell therapy, cell engineering, and biologics production for patients requiring treatment.
Investors Include:
GordonMD Global Investments, Partners Investment, Cystic Fibrosis Foundation, D1 Capital Partners, General Inception, Fidelity Management & Research, Retinal Degeneration Fund, EPIQ Capital Group, PBM Capital, SymBiosis Capital Management, T. Rowe Price Group.